Literature DB >> 3260073

Production and administration to dogs of aerosols of alpha-1-proteinase inhibitor.

R M Smith1, R G Spragg.   

Abstract

The feasibility of aerosol administration of alpha-1-proteinase inhibitor (human) (A1PI) was assessed. Of three different methods of aerosolizing A1PI that were evaluated, an ultrasonic nebulizer was found to be best suited to the present purpose, producing particles of a size that allowed them to reach the distal air spaces of the lung and that retained specific A1PI anti-elastase activity. Administration of 20 mg/kg of A1PI and 150 microCi of 131iodine-A1PI to three dogs was accomplished without complications. Gamma camera scans documented a relatively homogenous distribution throughout the lungs. Bronchial lavage fluid that was recovered from the lungs of the dogs six hours after administration contained large amounts of human A1PI and showed a proportional elevation of anti-elastase activity. There was no evidence of acute toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260073     DOI: 10.1016/0002-9343(88)90158-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route.

Authors:  R C Hubbard; R G Crystal
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.

Authors:  R C Hubbard; N G McElvaney; S E Sellers; J T Healy; D B Czerski; R G Crystal
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

3.  Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep.

Authors:  R M Smith; L D Traber; D L Traber; R G Spragg
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.